An Educational Initiative for Pharmacists and Physicians
About the Series
This educational activity will explore the evolving issues, key questions and controversies associated with the use of immunotherapies for the treatment of patients with melanoma and lung cancer. Discussion will include an overview of cancer immunobiology, available and emerging immune checkpoint inhibitors, clinical efficacy and safety experience, current and expanding indications, rationale and evidence for combination therapies. The use of biomarkers to predict response, management of immune-related adverse events, and patient education will also be explored. Patient cases will be used to highlight therapy selection as well as adverse effects and toxicity management strategies.
Part 1: On-Demand Activity
Practice Essentials for Using Immune Checkpoint Inhibitors to Treat Lung Cancer and Melanoma
Part 2: Ask the Experts Webinar
Wednesday, March 25, 2020, 1:00 - 2:00 p.m. ET
This reinforcement activity features pharmacist and physician faculty continuing the discussion from Part 1 and addressing additional questions posed by learners.
Part 3: Engaging the Experts
Listen to interviews with faculty on key topics via podcast or on the activity website.